Voyager Therapeutics (VYGR) Accounts Payables (2014 - 2026)

Voyager Therapeutics has disclosed Accounts Payables across 13 years of filings, most recently posting $2.7 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $2.7 million, up 3.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 million (up 3.38% YoY), and the FY2025 annual result was $5.0 million, up 25.45% from the prior year.
• Accounts Payables came in at $2.7 million for Q1 2026 at Voyager Therapeutics, down from $5.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.6 million in Q1 2024 to a low of $1.2 million in Q1 2022.
• The 5-year median for Accounts Payables is $2.6 million (2024), against an average of $2.8 million.
• Across the five-year window, Accounts Payables surged 347.04% in 2022 and slumped 65.25% in 2025, its largest moves.
• Voyager Therapeutics' Accounts Payables stood at $2.6 million in 2022, then sank by 37.49% to $1.6 million in 2023, then jumped by 149.13% to $4.0 million in 2024, then increased by 25.45% to $5.0 million in 2025, then sank by 45.68% to $2.7 million in 2026.
• The last three Accounts Payables figures came in at $2.7 million (Q1 2026), $5.0 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.